| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2288 |
| Trial ID | NCT04231747 |
| Disease | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CC-97540 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
| Year | 2020 |
| Country | Canada|United States |
| Company sponsor | Juno Therapeutics, a Subsidiary of Celgene |
| Other ID(s) | CC-97540-NHL-001|U1111-1244-9049 |
| Cohort 1 | |||||||||
|
|||||||||